Biotransplant, Inc.

Universitè Catholique De Louvain

Ruth A Kaplan

Dominique Latinne

Mary E White-Scharf

Thomas Kieber-Emmons

Christina E Postema

Herve Bazin

Manfred Baetscher

Hervé Bazin

Donna E Akiyoshi

The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.

LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation

The present invention provides for a method of isolating and/or propagating porcine stem cells, more specifically pluripotential porcine embryonic stem cells. The pluripotential cells are isolated and/or propagated by the use of a selectable marker gene which is inserted into the genetic material of the cells, and which permits the survival and growth of the porcine embryonic stem cells. The selectable marker gene is inserted so as to be regulated by a control or promoter polynucleotide sequence in the embryonic stem cells, for example the promoter polynucleotide sequence being the porcine Oct-4 promoter sequence of the present invention. The invention also provides for a transgenic pig which will constitute a source of the pluripotent cells.

Porcine Oct-4 promoter

Methods of inhibiting T cell mediated immune responses with humanized

Growing community of inventors

Tewsbury, MA, United States of America

Ruth A Kaplan